Pharma Equity Group A/S Cl A - Asset Resilience Ratio

Latest as of June 2019: 2.24%

Pharma Equity Group A/S Cl A (PEG) has an Asset Resilience Ratio of 2.24% as of June 2019. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

Dkr1.72 Million

≈ $269.58K USD Cash + Short-term Investments

Total Assets

Dkr77.09 Million

≈ $12.06 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2008–2018)

This chart shows how Pharma Equity Group A/S Cl A's Asset Resilience Ratio has changed over time. See Pharma Equity Group A/S Cl A leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.

Liquid Assets Composition Over Time

This chart breaks down Pharma Equity Group A/S Cl A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Pharma Equity Group A/S Cl A.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Dkr0.00	0%
Short-term Investments	Dkr1.72 Million	2.24%
Total Liquid Assets	Dkr1.72 Million	2.24%

Asset Resilience Insights

Limited Liquidity: Pharma Equity Group A/S Cl A maintains only 2.24% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Pharma Equity Group A/S Cl A Industry Peers by Asset Resilience Ratio

Compare Pharma Equity Group A/S Cl A's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Samsung Biologics Co Ltd KO:207940	Biotechnology	5.66%
Abivax SA PA:ABVX	Biotechnology	2.34%
Merus BV NASDAQ:MRUS	Biotechnology	29.69%
Suzhou Zelgen Biopharmaceuticals Co Ltd SHG:688266	Biotechnology	0.54%
Beijing Hotgen Biotech Co Ltd SHG:688068	Biotechnology	20.87%
Inner Mongolia Furui Med Sci SHE:300049	Biotechnology	2.34%
Starlake Bioscience Co Inc Zhaoqing Guangdong SHG:600866	Biotechnology	0.29%
Wuhan Keqian Biology Co Ltd SHG:688526	Biotechnology	19.42%

Annual Asset Resilience Ratio for Pharma Equity Group A/S Cl A (2008–2018)

The table below shows the annual Asset Resilience Ratio data for Pharma Equity Group A/S Cl A.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2018-09-30	2.13%	Dkr1.72 Million ≈ $269.58K	Dkr80.84 Million ≈ $12.65 Million	+1.06pp
2016-09-30	1.07%	Dkr1.35 Million ≈ $210.90K	Dkr125.75 Million ≈ $19.67 Million	-0.27pp
2015-09-30	1.34%	Dkr1.69 Million ≈ $264.10K	Dkr126.25 Million ≈ $19.75 Million	-5.61pp
2012-09-30	6.95%	Dkr35.00 Million ≈ $5.48 Million	Dkr503.85 Million ≈ $78.83 Million	+0.05pp
2011-09-30	6.89%	Dkr35.00 Million ≈ $5.48 Million	Dkr507.76 Million ≈ $79.44 Million	-69.48pp
2008-09-30	76.37%	Dkr199.84 Million ≈ $31.27 Million	Dkr261.67 Million ≈ $40.94 Million	--

pp = percentage points

About Pharma Equity Group A/S Cl A

CO:PEG Denmark Biotechnology

Market Cap

$16.52 Million

Dkr105.57 Million DKK

Market Cap Rank

#25715 Global

#116 in Denmark

Share Price

Dkr0.09

Change (1 day)

+4.88%

52-Week Range

Dkr0.07 - Dkr0.15

All Time High

Dkr2.81